Professional article
Open access

Inhibiteurs du SGLT2 : que des bénéfices?

Other titleSGLT2 inhibitors : only beneficial ?
Published inRevue médicale suisse, vol. 17, no. 741, p. 1072-1077
Publication date2021-06-02

SGLT2 inhibitors are more and more prescribed in the treatment of type 2 diabetes. Their cardioprotective and nephroprotective effects make them particularly attractive. However, it is important to be aware of their potential side effects. This article aims to summarize the actual evidence regarding the most studied ones. Euglycemic ketoacidosis, genital infections and hypovolemia have been well described. Evidence is less robust regarding the increased risk of amputations, fractures, urinary tract infection or acute kidney disease. This article also aims to summarize some key messages to discuss with patients, in order to prevent the occurrence of euglycemic ketoacidosis and hypovolemia.

  • Inhibiteur
  • Diabète de type 2
  • Amputation, Surgical
  • Diabetes Mellitus, Type 2 / drug therapy
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Ketosis
  • Sodium-Glucose Transporter 2 Inhibitors / therapeutic use
  • Urinary Tract Infections
Citation (ISO format)
SCIOTTO, Lucie, JORNAYVAZ, François. Inhibiteurs du SGLT2 : que des bénéfices? In: Revue médicale suisse, 2021, vol. 17, n° 741, p. 1072–1077. doi: 10.53738/REVMED.2021.17.741.1072
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation09/30/2022 11:53:00 AM
First validation09/30/2022 11:53:00 AM
Update time03/16/2023 10:32:03 AM
Status update03/16/2023 10:32:02 AM
Last indexation08/31/2023 10:31:08 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack